Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in a Real-World Cohort (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-425; Location: LEVEL 3, HALL B3; "The clinically based R-PSS tool may help identify patients at high risk of treatment failure, allowing optimal patient selection for novel therapies and/or allo-HSCT referral soon after ruxolitinib initiation. AIC: Akaike information criterion, AUD: area under the curve, BM: bone marrow, C-index: concordance index, DIPSS: Dynamic Prognostic Scoring System, HR: hazard ratio, HSCT: hematopoietic stem cell transplantation, IDI: integrated discrimination improvement, IWGMNR: International Working Group-Myelofibrosis Research and Treatment, JAKi: Janus kinase inhibitor, LCM: left costal margin, NRI: net reclassification index, OS: overall survival, PB: peripheral blood, PMF: primary myelofibrosis, R-PSS: Ruxolitinib Prognostic Scoring System, RR6: Response to Ruxolitinib after 6 months prognostic model, SMF: secondary myelofibrosis, SR: spleen response."
Clinical • Real-world • Real-world evidence • Myelofibrosis • Oncology
|
|
Alessandro Laganà MD; Emilia Scalzulli MD; Maria Laura Bisegna MD; Ida Carmosino MD; Deborah Kasmi MD; Martina Gherardini MD; Anna Laura Faccini MD; Costanza Andriola MD; Maurizio Martelli MD; Massimo Breccia MD
|